Brief: JPMorgan Chase & Co's Long Position In Haohai Biological Technology Rises To 6.02% - HKEX Filing
Sept 14 (Reuters) - Shanghai Haohai Biological Technology Co
Ltd:
* JPMORGAN CHASE & CO'S LONG POSITION IN SHANGHAI HAOHAI
BIOLOGICAL TECHNOLOGY 6826.HK INCREASED TO 6.02% ON SEPT 9
FROM 5.16% - HKEX FILING
Source text https://di.hkex.com.hk/di/NSForm2.aspx?fn=CS20210914E00099&sa2=ns&sid=119410&sd=14/09/2020&ed=14/09/2021&sa1=cl&scsd=14/09/2020&sced=14/09/2021&sc=06826&src=Main&lang=EN&tk=ds
Further company coverage: 6826.HK
(Reporting by Hong Kong newsroom)
((twinnie.siu@tr.com; 852-3462 7715;))
Recent news on Shanghai Haohai Biological Technology
See all newsChina's Haohai Biological H1 revenue falls, partly hurt by end of Brighten Optix distribution
Brief: Shanghai Haohai Biological Technology Says Resignation Of Hou Yongtai As Exec Director, Chair
Brief: Shanghai Haohai Biological Technology Updates On Investigation Of Jiang Wei's Suspected Insider Trading Case
Brief: Shanghai Haohai Biological Technology Proposes To Elect Tian Min As An Additional Executive Director
Brief: Shanghai Haohai Biological Technology Posts Qtrly Net profit Attributable Of RMB73.6 Mln.